Navigation Links
Regeneron Announces June 2012 Investor Conference Presentations
Date:5/30/2012

TARRYTOWN, N.Y., May 30, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:

  • Goldman Sachs Global Healthcare Conference 2012 at 7:00 p.m. Eastern Time (4:00 p.m. Pacific Time) on Tuesday, June 5, 2012
  • Jefferies 2012 Global Healthcare Conference at 10:30 a.m. Eastern Time on Thursday, June 7, 2012
  • The sessions may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page.  Archived versions of the presentations will be available for thirty days after the live webcasts. 

    Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, ARCALYST® (rilonacept) Injection for Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products.   A regulatory application has also been submitted to the FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA® in a third indication, and with product candidate sarilumab.  Earlier-stage clinical programs are underway with nine additional monoclonal antibodies.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information: Manisha Narasimhan, Ph.D.

    Peter DworkinInvestor Relations

    Corporate Communications914-847-5126

    914-847-764manisha.narasimhan@regeneron.com 

    peter.dworkin@regeneron.com


    '/>"/>
    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
    2. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
    3. Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
    4. Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
    5. Regeneron Announces February 2012 Investor Conference Presentations
    6. Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
    7. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
    8. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
    9. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
    10. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
    11. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/7/2017)... 2017 NuvoAir (formerly called Pond Healthcare ... a partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry ... the leading mobile spirometry platform and Novartis, commitment to address ... ... ...
    (Date:9/6/2017)... 2017  Medical professionals are expected to ... treating their patients. Medical simulations offer clinicians ... patients. Simulation provides a safe method for ... procedures, refine techniques and build confidence, without ... technology, such as augmented reality, will now ...
    (Date:9/5/2017)... Colo. , Sept. 5, 2017 Sapheneia ... XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party Vendor ... existing CT scanners and allows compliance with current MITA ... Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically designed ... and alerts of potential radiation doses over a predefined ...
    Breaking Medicine Technology:
    (Date:9/20/2017)... (PRWEB) , ... September 20, ... ... a software company specializing in medical device compliance and commercialization, has just ... risk management activities. , FDA is more adamant than ever about medical ...
    (Date:9/20/2017)... ... September 20, 2017 , ... Demand ... at the East-coast edition of MarTech: The Marketing Tech Conference October 2–4, at ... more than 40 speakers — representing such thought-leading companies as JP Morgan ...
    (Date:9/20/2017)... ... September 20, 2017 , ... ... and innovation, the company recently unveiled a redesigned website. The new site – ... work of building owners, architects, contractors and other industry users that Garland serves. ...
    (Date:9/20/2017)... ... September 20, 2017 , ... Each year Athletic ... National Athletic Trainers’ Association Annual Clinical Symposium and Expo. New research is revealed, ... when Athletic Trainers are acknowledged by their peers with accolades and highly prestigious ...
    (Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... digital and social campaign, “Humans With Vaginas.” The goal is to ignite conversation ... of non-toxic personal care products. The brand has declared September “Humans with Vaginas” ...
    Breaking Medicine News(10 mins):